LAPAHOPE 

DESCRIPTION

Lapahope consist of small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. Lapahope tablets are classified as anti-neoplastic agent, which is orally active drug used for treating breast cancer. Lapahope tablets are comes under biological category which is targeted chemotherapy. These drugs work by ‘targeting’ essential proteins (receptors) which make cancer cells grow.

INDICATION OF LAPAHOPE

• With combination of capecitabine is indicated for treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab
• With combination of letrozole is indicated for treatment of postmenopausal women with hormone receptor-positive and HER2-positive breast cancer for whom hormonal therapy is indicated

MECHANISM OF LAPAHOPE

Lapatinib belongs to a type of targeted cancer regimen (biological therapy) called a protein kinase inhibitor (TKI). It is a targeted therapy required for cancers which have large amounts of a protein called HER2 (human epidermal growth factor receptor 2). 

Some breast cancers have large amounts of HER2. They are called HER2 positive cancers. HER2 which makes the tumor cells develop and divide. Lapatinib blocks HER2 to make the cells stop developing or die. 

Absorption

The absorption of Lapahope is incomplete and insufficient, the maximum plasma concentration time of Lapatinib occurs relatively 4 hours after drug intake. The steady state reaches within 6 to 7 days

Distribution

Lapatinib is highly bounds to human plasma protein like albumin & alpha glycoprotein nearly 99%.

Metabolism

Lapatinib is a substrate of P-gp & BCRP and go through intensive metabolism by using CYPP3A4 & CYP3A5 with lesser contribution of CYP2C19 & CYP2C8.

Excretion

Lapahope in single dose reaches half- life time in 14.2 hours and repeated dosing reaches in 24 hours.

Elimination occurs via feces & urine.

DOSAGE REGIMENS AND ADMINISTRATION OF LAPAHOPE

In HER2 positive advanced breast cancer:

The recommended dose of Lapahope is 1250mg should be administered orally as a single dose on day 1 to 21repeatedly combined with Capecitabine 2000mg/m²/day (should be taken orally in 2 doses relatively 12 hours apart) on day 1 to 14 in continuous 21-day cycle.

Totally 5 tablets of Lapahope should be taken at a time as whole.

In hormone receptor positive HER 2 positive advance breast cancer:

The prescribed dose is 1500mg should be administered orally as a single dose by combining with letrozole.

The prescribed dose of letrozole is 2.5mg as a once a day.

In these total 6 tablets of Lapahope should be administered as such.

Dose alteration:

Cardiac events:

In patients with reduction of left ventricular ejection fraction with grade 2, treatment with Lapahope should be discontinued.

In this condition, the dose of Lapahope should be initiated with 1000mg/day in combination with Capecitabine; whereas in combination with letrozole the dose of Lapahope restated with 1250mg/day after 2 weeks, if LVEF turns to normal.

Hepatic impairment:

For patient with severe hepatic impairment, the dose reduced from 1250mg/day to 750mg/day or from 1500mg/day to 1000mg/day.

Diarrhea:

Lapahope tablets should be restarted once the severity of diarrhea may reduce to grade I. permanently discontinued if diarrhea is persisting.

Concurrent use of CYP3A4 inhibitors:

Lapahope should not be combined with CYP3A4 inhibitors; because of elevation of plasma concentration of Lapatinib occurs. For eradicate this effect, the dose of Lapahope should be reduced to 500mg/day.

Concurrent use of CYP3A4 inducers:

In this combinational study, the dose of Lapahope should be elevate from 1250mg/day to 4500mg/day or from 1500mg/day to 5500mg/day.

In other toxicity:

Postpone or stop the Lapahope therapy may happens, in case of developing higher grade of toxicities which is greater than or equal to grade II.

Lapahope use in combination with Capecitabine should be resume at lower doses 1000mg/day and whereas in combination with letrozole should be resume at lower dose of 1250mg/day.

Lapahope tablets should be taken without food; administer 1 hour earlier or 2 hours after the food uptake.

Capecitabine should be administered with food or taken within 30 minutes after ingestion of food.

LAPAHOPE CAUSED SIDE EFFECTS

• Alopecia
• Pruritus
• Nail disorders
• Asthenia
• Headache
• Epistaxis
• Diarrhea
• Nausea
• Vomiting
• Stomatitis
• Back pain
• Dyspnea
• Insomnia
• Elevation of hemoglobulin, platelets, neutrophils
• Increase in AST & ALT, bilirubin
• Reduction of left ventricular ejection fraction
• Liver toxicity
• Interstitial lung disease
• Anaphylactic reactions
• Stevens Johnson syndrome
• Ventricular arrhythmias
• QT prolongation

DRUG- DRUG INTERACTION

• Midazolam concomitant use with Lapahope, will raise the exposure of Midazolam.
• Increase in paclitaxel exposure occurs while combination with Lapahope.
• Serum digoxin concentration should be checked periodically before starting the combination. If digoxin level in serum is greater than 1.2ng/ml, then the dose of digoxin reduced taken with half.
• Lapahope tablets are inhibition of CYP3A4, CYP2C8 & P-gp drug transporters; weak inhibitor of CYP3A4.
• The dose reduction of these concurrent uses of substrate drug should be advised, while allowing Lapahope combined with drugs metabolized by CYP3A4, CYP2C8 or P-gp.
• When interaction of Ketoconazole with Lapahope, the dose reduced to 200mg as two times a day for 7 days.
• Interaction of Carbamazepine with Lapahope, the dose of carbamazepine at 100mg as two times a day for 3 days & 200mg for two times a day for 17 days, the exposure of Lapahope reduced to 72%.

CONTRAINDICATIONS

A hypersensitivity reaction occurs in patients who are contraindicated to the component present in Lapahope tablet.

PRECAUTIONS

Diarrhea: Severe diarrhea may lead to dehydration causes death also; if patient do not recover from this severity must discontinue with this therapy.

Reduction in left ventricular ejection fraction: Caution should be taken while using Lapahope in patient with LVEF

The virulence of LVEF should be decreased within first 12 weeks of treatment

Before starting the therapy with Lapahope, patient must be examining thoroughly if suspected with LVEF or not.

Liver damage: Increasing level of AST, ALT or bilirubin may leads to liver injury

To prevent this condition, periodic LFT should be maintained

Interstitial lung disease: Patient should be monitored with pulmonary symptoms and provide supportive measures.

On severe condition, treatment should be interrupt or discontinue

QT prolongation: Monitor ECG periodically

Provide substituent for this adverse condition

Hypokalemia and hypomagnesemia correction should be takes place

PREGNANCY

Pregnancy category: D

Lapahope should not be used in pregnancy condition

The potency of Lapahope has not been evaluated in pediatric patients.

In both renal & hepatic impairment patients, caution should be taken while using this medication

LACTATION

Breast feeding should not be allowed

STORAGE AND HANDLING

Lapahope carton should be kept at 25^oC (77^oF).

Keep the carton free from moisture, heat or light

MISSED DOSE

Missed dose should be skipped and follow the regular dosing schedule for avoiding adverse conditions. If missed dose occurs, it should not be resume and continue the next schedule.